The European Commission has granted marketing authorization to Novavax for its updated COVID-19 vaccine, Nuvaxovid XBB.1.5, for the 2023/2024 vaccination season. This approval follows a positive recommendation from the European Medicines Agency (EMA) and is intended for use in individuals aged 12 years and older.

The updated vaccine targets the Omicron XBB.1.5 subvariant, aligning with guidance from the World Health Organization and the EMA to address the evolving SARS-CoV-2 virus. Novavax's protein-based vaccine offers an alternative to mRNA-based COVID-19 vaccines currently available in the European Union.

This development supports ongoing public health efforts to provide effective vaccination options as new variants emerge. For more information, visit the EMA announcement.